Victoria Baltrus, serving as the Chief Accounting Officer for Oscar Health, Inc. (NASDAQ:OSCR), completed a divestment of company equity on June 2, 2026. The executive liquidated a total of 1,523 shares of Oscar Health Class A Common Stock, realizing a combined proceeds value of $33,416. The sales were executed within a specific price corridor ranging from $21.74 to $22.45 per share.
The transaction structure involved two distinct phases of share disposal. In the initial phase, Baltrus sold 1,091 shares at a weighted average price of $21.74 per share. These specific shares were sold across multiple transactions, with execution prices fluctuating between $21.03 and $22.02. In a subsequent phase, an additional 432 shares were liquidated at a weighted average price of $22.45 per share. The individual transactions for this portion ranged from $22.03 to $22.96.
These sales were conducted under the framework of a Rule 10b5-1 trading plan, which Baltrus formally established on August 8, 2025. The explicit purpose of these transactions was to satisfy tax withholding obligations associated with the vesting of previously granted equity awards. Following the completion of these sales, Baltrus maintains a direct holding of 214,589 shares of Oscar Health Class A Common Stock.
The insider transaction occurs against a backdrop of recent market volatility for Oscar Health. The stock has declined 8.2% over the past week. Despite this recent pullback, shares remain up 43% year-to-date. According to InvestingPro analysis, the stock appears undervalued at current levels, placing it among opportunities on the most undervalued stocks list. For deeper insights into Oscar Health's valuation and growth prospects, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities.
Recent corporate developments highlight strong operational metrics for Oscar Health. The company reported a significant earnings beat for the first quarter of 2026. Oscar Health achieved earnings per share of $2.07, nearly doubling the forecasted $1.06, although it faced a revenue shortfall. This development highlights Oscar Health's strong profitability metrics.
Market sentiment also shifted following an upgrade by Wells Fargo. The bank upgraded Oscar Health's stock rating from Underweight to Equal Weight, raising the price target from $11 to $20. Analyst Stephen Baxter expressed growing confidence in the exchange market trajectory for 2026, despite limited visibility beyond that period.
Corporate structure adjustments were also announced. Oscar Health announced a change in Mario Schlosser's role and compensation agreement. Schlosser, formerly the President of Technology and Chief Technology Officer, has transitioned to Co-Founder & Advisor to the CEO. He will continue to support the company's artificial intelligence and digital health initiatives while remaining on the Board of Directors.
Oscar Health IncFollowAnalyze OSCRIncluded in our AI-picked strategies·Review strategies23.59▲+3.09(+15.07%)Closed23.600.00(0.00%)After Hours·17:21:571D1W1M6M1Y5YMaxAnalyze OSCRThis article was generated with the support of AI and reviewed by an editor. For more information see our T&C.Is OSCR a bargain right now?
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for OSCR plus thousands of other stocks and find your next hidden gem with massive upside.
See Undervalued Stocks